Hepion Pharmaceuticals, Inc. (HEPA)
Largest Insider Buys in Sector
HEPA Stock Price History Chart
HEPA Stock Performance
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Insider Activity of Hepion Pharmaceuticals, Inc.
Over the last 12 months, insiders at Hepion Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Hepion Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Hepion Pharmaceuticals, Inc. have bought $82,443 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $7,625 was made by Wijngaard Peter (director) on 2023‑11‑27.
List of Insider Buy and Sell Transactions, Hepion Pharmaceuticals, Inc.
| 2023-11-27 | director | 2,500 0.0602% | $3.05 | $7,625 | -55.03% | |||
| 2023-11-24 | director | 2,500 0.058% | $3.09 | $7,725 | -56.45% | |||
| 2023-09-19 | director | 1,000 0.0252% | $5.64 | $5,640 | -61.75% | |||
| 2023-09-18 | CEO and Director | 1,600 0.0419% | $5.60 | $8,960 | -59.96% | |||
| 2023-09-15 | CEO,CSO and Director | 1,600 0.0429% | $5.40 | $8,640 | -57.14% | |||
| 2023-09-15 | director | 2,000 0.0556% | $5.60 | $11,201 | -57.14% | |||
| 2021-02-18 | CEO and Director | 20,000 0.0017% | $2.00 | $40,000 | -29.09% | |||
| 2021-02-18 | Chief Financial Officer | 10,000 0.0009% | $2.00 | $20,000 | -29.09% | |||
| 2021-02-16 | director | 10,000 0.0009% | $2.20 | $22,000 | -29.73% | |||
| 2020-12-18 | director | 20,000 0.2035% | $1.91 | $38,200 | -13.40% | |||
| 2020-12-08 | CEO and Director | 25,000 0.2327% | $1.58 | $39,418 | -2.86% | |||
| 2020-12-02 | director | 7,000 0.0696% | $1.53 | $10,710 | +6.92% | |||
| 2020-12-01 | director | 12,000 0.1247% | $1.66 | $19,920 | +3.03% | |||
| 2020-11-25 | Chief Financial Officer | 4,500 0.0477% | $1.62 | $7,290 | +7.59% | |||
| 2017-06-20 | CFO | 20,000 0.0017% | $0.65 | $13,000 | -43.47% | |||
| 2016-02-18 | Chief Executive Officer | 10,000 0.0018% | $1.00 | $10,000 | +8.65% | |||
| 2015-11-30 | Chief Executive Officer | 500 <0.0001% | $2.15 | $1,075 | -51.77% | |||
| 2015-11-23 | Chief Executive Officer | 2,500 0.0004% | $1.64 | $4,100 | -38.42% | |||
| 2014-03-04 | director | 4,393 0.0015% | $1.49 | $6,546 | +12.91% |
Insider Historical Profitability
| Foster Robert T | CEO and Director | 50470 0.7253% | $0.62 | 4 | 0 | <0.0001% |
| Cavan John T | Chief Financial Officer | 14800 0.2127% | $0.62 | 3 | 0 | <0.0001% |
| SAPIRSTEIN JAMES | Chief Executive Officer | 13000 0.1868% | $0.62 | 3 | 0 | |
| JACOB GARY S | director | 12059 0.1733% | $0.62 | 1 | 0 | +3.03% |
| Wijngaard Peter | director | 9501 0.1365% | $0.62 | 6 | 0 | <0.0001% |
| BRANCACCIO JOHN P | director | 7008 0.1007% | $0.62 | 2 | 0 | +6.92% |
Institutional Investor Ownership
| Armistice Capital Llc | $971,100.00 | 6.73 | 390,000 | -6.7% | -$69,720.00 | <0.01 | |
| The Vanguard Group | $391,826.00 | 2.71 | 157,360 | -1.86% | -$7,432.64 | <0.0001 | |
| BlackRock | $206,555.00 | 1.43 | 82,954 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $96,724.00 | 0.67 | 38,833 | +11.24% | +$9,773.77 | <0.0001 | |
| State Street | $39,033.00 | 0.27 | 15,676 | 0% | +$0 | <0.0001 | |
| Susquehanna International Group | $36,441.00 | 0.25 | 14,635 | 0% | +$0 | <0.0001 | |
| PNC Financial Services | $19,619.00 | 0.14 | 7,879 | +173.67% | +$12,450.18 | <0.0001 | |
| Tower Research Capital | $4,731.00 | 0.03 | 1,900 | +17.5% | +$704.67 | <0.0001 | |
| Morgan Stanley | $3,378.00 | 0.02 | 1,357 | -6.09% | -$219.06 | <0.0001 | |
| Group One Trading | $844.00 | 0.01 | 339 | 0% | +$0 | <0.0001 | |
| UBS | $455.00 | <0.01 | 183 | +9,050% | +$450.03 | <0.0001 | |
| AdvisorNet Financial | $438.00 | <0.01 | 176 | New | +$438.00 | <0.0001 | |
| Macquarie Group | $0 | <0.01 | 88 | New | +$0 | <0.0001 | |
| Advisor Group Holdings Inc | $281.00 | <0.01 | 113 | -0.88% | -$2.49 | <0.0001 | |
| Wells Fargo | $85.00 | <0.01 | 34 | +3.03% | +$2.50 | <0.0001 | |
| Barclays | $0 | <0.01 | 16 | 0% | +$0 | <0.0001 | |
| GRP Financial | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
| Harbor Investment Advisory | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
| Bank of America | $2.00 | <0.01 | 1 | -99.12% | -$226.00 | <0.0001 | |
| Allworth Financial Lp | $3.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
| SignatureFD | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 20 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $27.00 | <0.01 | 11 | -99% | -$2,680.36 | <0.0001 |